FDA
-
-
-
-
-
-
-
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
-
-
-
-
-
-
-
United Therapeutics TETON-1 study meets primary endpoint for lung disease treatment
-
-
-
-
-
-
-
United Therapeutics reports positive phase 1 results for bioengineered liver
-
-
-
-
-
-
-
United Therapeutics' Tyvaso meets primary endpoint in IPF study
-
-
-
-
-
-
-
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
United Therapeutics Announces Successful World’s First UKidney Transplant
-
-
-
-
-
-
-
Morgan Stanley Downgrades United Therapeutics Corp. (UTHR) to Equalweight
-
326,369 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

